

Information Regarding Clinical Trial

Title	Phase 1b/II study combining Olaratumab with Abraxane and Gemcitabine. Phase 1b will consist of an open-label dose finding study and Phase II will be a double-blinded, randomized study comparing Olaratumab plus Abraxane and Gemcitabine versus placebo plus Abraxane and Gemcitabine with or without Olaratumab in the Treatment of Metastatic Pancreatic Cancer
Protocol Number	<u>15B-MC-JGDP</u>
Sponsor	<u>Eli Lilly</u>
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	No prior treatment for metastatic disease No prior treatment with nab-paclitaxel Have known CNS mets